Molecular staging of lymph nodes from patients with esophageal adenocarcinoma

Clinical Cancer Research

Volumn 11, Issue 3, 2005, Pages 1099-1109

  Xi, Liqiang ^a,e   Luketich, James D ^a,c   Raja, Siva ^a   Gooding, William E ^b,c   Litle, Virginia R ^a,e   Coello, Michael C ^a   Finkelstein, Sydney D ^d   Chestney, Melissa L ^a   Landreneau, Rodney J ^a,c   Hughes, Steven J ^a,c   Godfrey, Tony E ^a,c,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d RedPath Integrated Pathology   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

ALGORITHM; ARTICLE; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HUMAN CELL; LYMPH NODE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR;

ADENOCARCINOMA; ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERMEDIATE FILAMENT PROTEINS; KERATIN-20; KERATIN-7; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; MICROFILAMENT PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 19944433818     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998;115:660-9.
2. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000;232:225-32.
3. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med 1997;337:1188-94.
4. Mueller JD, Stein HJ, Oyang T, et al. Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction. Cancer 2000;89:1874-82.
5. Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998;83:858-66.
6. N0 esophageal squamous cell carcinoma. Cancer Lett 2000;153:189-97.
7. Bonavina L, Ferrero S, Midolo V, Buffa R, Cesana B, Peracchia A. Lymph node micrometastases in patients with adenocarcinoma of the esophagogastric junction. J Gastrointest Surg 1999;3:468-76.
8. N0) esophageal carcinoma. J Surg Oncol 2002;79:224-9.
9. Komukai S, Nishimaki T, Watanabe H, Ajioka Y, Suzuki T, Hatakeyama K. Significance of immunohistochemically demonstrated micrometastases to lymph nodes in esophageal cancer with histologically negative nodes. Surgery 2000;127:40-6.
10. Vazquez-Sequeiros E, Wang L, Burgart L, et al. Occult lymph node metastases as a predictor of tumor relapse in patients with node-negative esophageal carcinoma. Gastroenterology 2002;122:1815-21.
11. Kijima F, Natsugoe S, Takao S, et al. Detection and clinical significance of lymph node micrometastasis determined by reverse transcription-polymerase chain reaction in patients with esophageal carcinoma. Oncology 2000;58:38-44.
12. Godfrey TE, Raja S, Finkelstein SD, Gooding WE, Kelly LA, Luketich JD. Prognostic value of quantitative reverse transcription-polymerase chain reaction in lymph node-negative esophageal cancer patients. Clin Cancer Res 2001;7:4041-8.
13. Kassis ES, Nguyen N, Shriver SP, Siegfried JM, Schauer PR, Luketich JD. Detection of occult lymph node metastases in esophageal cancer by minimally invasive staging combined with molecular diagnostic techniques. JSLS 1998;2:331-6.
14. Luketich JD, Kassis ES, Shriver SP, et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg 1998;66:1715-8.
15. Glickman JN, Torres C, Wang HH, et al. The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma. Cancer 1999;85:769-78.
16. Cote RJ, Peterson HF, Chaiwun B, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999;354:896-900.
17. Fisher ER, Swamidoss S, Lee CH, Rockette H, Redmond C, Fisher B. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;42:2025-31.
18. Jannink I, Fan M, Nagy S, Rayudu G, Dowlatshahi K. Serial sectioning of sentinel nodes in patients with breast cancer: a pilot study. Ann Surg Oncol 1998;5:310-4.
19. Isozaki H, Okajima K, Fujii K. Histological evaluation of lymph node metastasis on serial sectioning in gastric cancer with radical lymphadenectomy. Hepatogastroenterology 1997;44:1133-6.
20. Chen ZL, Perez S, Holmes EC, et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small cell lung carcinoma. J Natl Cancer Inst 1993;85:493-8.
21. Dobashi K, Sugio K, Osaki T, Oka T, Yasumoto K. Micrometastatic P53-positive cells in the lymph nodes of non-small cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg 1997;114:339-46.
22. Maruyama R, Sugio K, Mitsudomi T, Saitoh G, Ishida T, Sugimachi K. Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 1997;114:535-43.
23. Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol 1999;17:19-24.
24. Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol 2002;20:2930-6.
25. N0 lymph nodes of patients with completely resected nonsmall cell lung cancer: impact on recurrence and Survival. Ann Surg 2002;235:133-9.
26. Motomura K, Komoike Y, Inaji H, et al. Multiple sectioning and immunohistochemical staining of sentinel nodes in patients with breast cancer. Br J Surg 2002;89:1032-4.
27. Wong SL, Chao C, Edwards MJ, Simpson D, McMasters KM. The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am J Surg 2001;182:330-4.
28. Veronesi U, Zurrida S, Mazzarol G, Viale G. Extensive frozen section examination of axillary sentinel nodes to determine selective axillary dissection. World J Surg 2001;25:806-8.
29. Roberts CA, Beitsch PD, Litz CE, et al. Interpretive disparity among pathologists in breast sentinel lymph node evaluation. Am J Surg 2003;186:324-9.
30. Godfrey TE, Kim S-H, Chavira M, et al. Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5′ nuclease quantitative RT-PCR. J Mol Diagn 2000;2:84-91.
31. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated Levels of FMR1 mRNA in Carrier Males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000;66:6-15.
32. Godfrey TE, Kely LA. Development of quantitative RT-PCR assays for measuring gene expression. In: Phouthone K, Grant SG, editors. Molecular Toxicology Protocols. Humana Press; 2004.
33. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. BioTechniques 1998;24:954-8, 960, 962.
34. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton: Chapman & Hall/CRC; 1994.
35. Schroder CP, Ruiters MH, de Jong S, et al. Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer 2003;106:611-8.
36. Takes RP, Baatenburg de Jong RJ, Wijffels K, et al. Expression of genetic markers in lymph node metastases compared with their primary tumours in head and neck cancer. J Pathol 2001;194:298-302.
37. Mitas M, Cole DJ, Hoover L, et al. Real-time reverse transcription-PCR detects KS1/4 mRNA in mediastinal lymph nodes from patients with non-small cell lung cancer. Clin Chem 2003;49:312-5.
38. Mitas M, Mikhitarian K, Walters C, et al. Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel. Int J Cancer 2001;93:162-71.
39. Aerts J, Wynendaele W, Paridaens R, et al. A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol 2001;12:39-46.
40. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130:515-24.
41. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
42. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26:2-8.
43. Anderson SE, Minsky BD, Bains M, Kelsen DP, Ilson DH. Combined modality therapy in esophageal cancer: the memorial experience. Semin Surg Oncol 2003;21:228-32.
44. Lerut T, Coosemans W, Decker G, et al. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg 2003;126:1121-8.